SLC5A2 and hydrops fetalis: Among these, SGLT2 inhibitors, such as dapagliflozin and empagliflozin, have been shown to reduce HF-related events in patients with reduced ejection fraction (HFrEF), regardless of diabetes mellitus status [2,3].